Prognostic value of AR mutation in primary African American prostate cancer

AR 突变在非裔美国人原发性前列腺癌中的预后价值

• 批准号: 7989304
• 负责人: SHAHRIAR KOOCHEKPOUR
• 金额: $ 19.98万
• 依托单位: LSU HEALTH SCIENCES CENTER
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-07-01 至 2012-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7989304
• 关键词: Address; African American; Age; American; Androgen Receptor; Androgens; Benign; Biochemical; Cancer Patient; Cancer-Predisposing Gene; Caucasians; Caucasoid Race; Cell Line; Cells; Clinical; DNA; DNA Binding Domain; Data; Diagnostic Neoplasm Staging; Disease; Epidemiologist; Event; Exons; Family history of; Flow Cytometry; Frequencies; Gene Mutation; Gene Targeting; Genomics; Germ-Line Mutation; Gleason Grade for Prostate Cancer; Heterogeneity; Hormones; Incidence; Individual; Knowledge; Laboratories; Lasers; Lead; Malignant - descriptor; Malignant neoplasm of prostate; Molecular; Mutate; Mutation; Natural History; Outcome; PC3 cell line; Paraffin Embedding; Pathological Staging; Pathologist; Patients; Pattern; Prevalence; Prognostic Factor; Prognostic Marker; Prostate; Prostate-Specific Antigen; Radical Prostatectomy; Receptor Gene; Recurrence; Refractory; Refractory Disease; Reporting; Sampling; Somatic Mutation; Specimen; Staging; Staining method; Stains; Testing; Therapeutic; Therapeutic Intervention; Tissue Banking; Tissue Banks; Tissues; Tumor Volume; Tumor stage; cancer site; caucasian American; density; laser capture microdissection; men; mortality; novel; prognostic; prostate carcinogenesis; protein expression; public health relevance; receptor; receptor density; receptor expression; receptor-mediated signaling; tissue resource; tumor; tumor progression

DESCRIPTION (provided by applicant): Prostate cancer (PCa) incidence and mortality rate is higher in African American (AA) men than in Caucasian Americans (CAs). AA men with PCa also present with higher tumor volume, more advanced tumor stage, and higher Gleason grade. Prostate carcinogenesis and tumor progression are related strongly to the expression and activity of the androgen receptor (AR). Mutations and genomic amplification of AR also can increase AR expression and/or activity. In CAs, AR mutations are infrequent (<1%) in localized tumors, but occur at a higher frequency in advanced, metastatic, or hormone-refractory disease. In AAs, the prevalence of AR mutations and their prognostic significances in primary PCa are unknown. We discovered genomic amplification and somatic mutation of AR in a PCa cell line established by our laboratory from an AA patient with localized PCa. We analyzed a set of 91 radical prostatectomy samples (57 AAs and 34 CAs) in which we identified 8 AR mutations (7 somatic and 1 germline) in AA patients, but found no mutations in CA patients. These data led us to hypothesize that AR mutations in primary African Americans PCa is more frequent than expected and may contribute to disease aggressiveness or serve as a prognostic factor. Our Specific Aims are: Aim 1: Determine the prevalence of AR mutations in primary African Americans PCa. Exon-specific primers of the AR gene will be used to sequence genomic-DNA extracted from laser-captured cells of paraffin- embedded tissue sections of radical prostatectomy specimens in order to determine the prevalence of somatic AR mutations in 400 AA patients with primary untreated PCa, and compare this frequency of mutation with that observed in 100 equivalent CA patients. Aim 2: Determine the contribution of AR mutation to PCa heterogeneity in African Americans. Clinical and histopathological heterogeneity of PCa present a major challenge to therapeutic interventions. Differences in AR expression and microvascular density are considered as the two major contributors to PCa heterogeneity. We will use flow cytometry and immunohistochemical staining to examine AR and microvessel density in AA PCa with mutated AR. Aim 3: Define the prognostic significance of AR mutations in primary African American PCa. We will determine the prognostic significance of AR mutations alone or in combination with AR density or microvessel density in relation to clinical or histopathological variables including age, PSA, Gleason score, pathological stage, biochemical recurrence, and family history, with a focus on Gleason sum or pattern as a central prognostic marker. Significance: The results of this exploratory project will provide new knowledge about both the prevalence and prognostic value of AR mutations and may help us to understand better and address more effectively the potential racial disparity between PCa aggressiveness in AAs and CAs. PUBLIC HEALTH RELEVANCE: The incidences, mortality, and aggressiveness of prostate cancer (PCa) in African-American (AA) men are higher than in Caucasians. To understand and address the racial disparity of the disease aggressiveness, reliable prognostic factors are needed. Our discovery of a high frequency of androgen receptor mutations in untreated localized AA PCa might have prognostic significance that would provide us a more effective therapeutic approach.

描述（由申请人提供）：非裔美国人（AA）男性（AA）男性（CAS）的前列腺癌（PCA）发病率和死亡率高。具有PCA的AA男性还具有较高的肿瘤体积，更高级的肿瘤阶段和更高的Gleason等级。前列腺癌变和肿瘤进展与雄激素受体（AR）的表达和活性密切相关。 AR的突变和基因组扩增也可以增加AR表达和/或活性。在CAS中，AR突变在局部肿瘤中很少发生（<1％），但在晚期，转移性或激素不良疾病中以较高的频率发生。在AAS中，AR突变的患病率及其在原发性PCA中的预后意义尚不清楚。我们发现了由具有局部PCA的AA患者建立的PCA细胞系中AR的基因组扩增和体细胞突变。我们分析了一组91个根部的前列腺切除术样品（57 AA和34个CAS），其中我们在AA患者中鉴定了8个AR突变（7个体细菌和1种系），但在CA患者中没有发现突变。这些数据导致我们假设原发性非洲裔美国人PCA的AR突变比预期的要频繁，并且可能导致疾病的侵略性或作为预后因素。我们的具体目的是：目标1：确定初级非裔美国人PCA中AR突变的普遍性。 AR基因的外显子特异性引物将用于序列基因组-DNA，从根治性前列腺切除术的解毒膜嵌入组织切片的激光捕获细胞中提取，以确定400名AA患者在400 aa患者中的体育AR突变的普遍性，并与该突变的主要频率相比。目标2：确定非裔美国人对PCA异质性的AR突变的贡献。 PCA的临床和组织病理学异质性提出了治疗干预措施的主要挑战。 AR表达和微血管密度的差异被认为是PCA异质性的两个主要因素。我们将使用流式细胞术和免疫组织化学染色来检查具有突变AR的AA PCA中的AR和微血管密度。目标3：定义原发性非裔美国人PCA中AR突变的预后意义。我们将与临床或组织病理学变量相关的AR密度或微血管密度相对于包括年龄，PSA，PSA，GLEASON评分，病理学阶段，生化复发和家族史，并以AR密度或微血管密度结合使用AR密度或微血管密度的预后意义。意义：该探索性项目的结果将提供有关AR突变的患病率和预后价值的新知识，并可能有助于我们更好地理解和更有效地解决AAS和CAS的PCA侵略性之间的潜在种族差异。 公共卫生相关性：非裔美国人（AA）男性的前列腺癌（PCA）的事件，死亡率和侵略性高于高加索人。为了了解和解决疾病侵略性的种族差异，需要可靠的预后因素。我们发现未经处理的局部AA PCA中高频率的雄激素受体突变可能具有预后意义，这将为我们提供更有效的治疗方法。